glp 1 new drug GLP-1 Guidelines for Type 2 Diabetes in 2025 Weight loss drugs don't work
Description
The considerable cardiovascular benefits associated with specific GLP-1 agonists and the well-documented efficacy of GLP-1 agonists in diabetes care are two key drivers driving this industry ahead
It should be mentioned that in the Liraglutide Effect and Action in Diabetes (LEAD)-6 trial (duration 26 weeks) no difference was observed in estimated geometric mean calcitonin levels between liraglutide 1.8 mg once daily and exenatide 10 g twice daily [31]
Patients who experience rapid dose escalation may be more prone to fatigue and gastrointestinal symptoms
[DOI] [PubMed] [Google Scholar] 11.Mller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, et al
The study provides important insights for clinical practice and future research
